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Abstract
Objectives: Describe the time elapsed from the diagnosis to treatment with chemotherapy for
patients with breast and lung cancer at public and private hospitals in Buenos Aires.
Design: Retrospective cohort study.
Setting: Three public and three private academic hospitals in Buenos Aires.
Participants: Patients with breast (n = 168) or lung cancer (n = 100) diagnosis treated with
chemotherapy.
Main outcomes measures: Clinical and sociodemographic data were collected in a stratified sam-
ple. We used the Kaplan–Meier estimator to analyse the time elapsed and the log rank test to com-
pare both groups
Results: For breast cancer patients, median time elapsed between diagnosis and treatment with
chemotherapy was 76 days (95% CI: 64–86) in public and 60 days (95% CI: 52–65) in private hospi-
tals (P = 0.0001). For adjuvant and neoadjuvant treatments, median time was 130 (95% CI:
109–159) versus 64 (95% CI: 56–73) days (P < 0.0001) and 57 days (95% CI: 49–75) versus 26 (95%
CI: 16–41) days, respectively (P = 0.0002). There were no significant differences in the time from
first consultation to diagnosis. In patients with lung cancer, median time from diagnosis to treat-
ment was 71 days (95% CI: 60–83) in public hospitals and 31 days (95% CI: 24–39) in private
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hospitals (P = 0.0002). In the metastatic setting, median time to treatment was 63 days (95% CI:
45–83) in public and 33 (95% CI: 26–44) days in private hospitals (P = 0.005).
Conclusions: There are significant disparity in the access to treatment with chemotherapy for
patients in Buenos Aires, Argentina.
Key words: access, breast cancer, lung cancer, chemotherapy, Argentina
Introduction
Disparities in access to timely cancer care for patients constitute a signifi-
cant barrier in providing quality healthcare in low and middle-income
countries (LMICs) [1]. Adequate health coverage and efficient health sys-
tems are necessary factors to provide adequate access to cancer screening
and prevention, timely diagnosis and treatments [2–6]. Unfavorable
socioeconomic conditions such as unemployment, low education level
and income are related to higher odds of cancer diagnosis in advanced
stages leading to greater risk of disease recurrence and death [7–9].
Few studies have reported on the access to cancer diagnosis and
treatments in Latin America, showing significant differences in
delays to cancer care according to the type of health coverage [10–
14]. The health system in Argentina is comprised of three main pro-
viders: the public health system, private health insurances and
union-run or social security health insurance [15]. The public health
system provides universal coverage including access to public hospi-
tals and primary care facilities to all individuals free of charge, and
is financed from the state or national budget. Union-run health
insurance is provided by trade unions, to workers and their depen-
dents. It is funded by a compulsory payroll contribution from the
employees and employers. There are approximately 300 different
trade unions with diverse health care plans in Argentina. However,
some individuals and union-run insurance opt to sub-contract pri-
vate health plans who might provide higher quality medical care in
private hospitals to their beneficiaries [16]. In other cases, indivi-
duals with social security consult at public hospitals leading to high
levels of cross-coverage between health systems [17]. The private
health system is comprised of around 200 pre-paid health insurance
and is purchased by individuals or companies who pay to receive
care in private hospitals.
In Argentina, the National ‘Compulsory Medical Plan’ mandates
that all cancer-related treatments must be provided without cost to
insured patients by private and union-run health insurance. Patients
without health insurance rely on public hospitals and the provision
of drug supplies by the state for cancer care. Though the coverage
for medical attention and cancer-related treatments is mandatory,
timely access and the quality of cancer care can differ substantially
in this segmented health care system.
The primary objective of this study was to describe and compare
the time elapsed from breast and lung cancer diagnosis to treatment
with chemotherapy between public and private hospitals. Secondary
objectives were to describe the time elapsed from first consultation to
diagnosis of breast and lung cancer, describe epidemiological and clin-
ical characteristics of patients treated in both systems and evaluate
their association with the time elapsed from diagnosis to treatment.
Methods
This is a multicenter, retrospective cohort study performed at six
academic hospitals in the city of Buenos Aires. Three of these were
private hospitals assisting patients with private health insurance or
social security and three were public hospitals assisting patients
without private insurance, covered by social security or the public
health system.
Study population
Convenience sampling was performed, stratified by type of institu-
tion (public or private). Inclusion criteria were as follows: Adult
patients (≥ 18 years old) with diagnosis of non-small cell lung can-
cer (NSCLC) or breast cancer, stages I to IV treated with chemother-
apy from January 1st 2016. Chemotherapy could be delivered in the
adjuvant (given after surgery for tumor removal), neoadjuvant
(given before surgery) or metastatic settings (as palliative treatment)
for the treatment of patients with NSCLC or breast cancer.
Definitive chemoradiation (chemotherapy given concomitantly with
radiation therapy) was a treatment option solely for patients with
NSCLC. Patients were excluded if they were pregnant during cancer
diagnosis, unable to provide informed consent or unable to answer
the survey due to cognitive impairment.
The physician-consultation ratio for each institution was calcu-
lated by dividing the number of annual patient consults to the med-
ical oncology department by the number of physicians.
Procedure and data collection: Researchers from each institution
recruited the patients and obtained informed consent. All personal
information was deidentified to ensure patient anonymization
throughout the study course. The research team developed a survey
addressing epidemiological and socio-economic factors, including
education level, familial composition, income, employment, geo-
graphical localization, transportation, and health insurance. This
survey was validated prior to study initiation in a cohort of 30 eli-
gible patients, though those results were not included in the final
analysis. Once the participant consented, the researcher adminis-
tered the survey verbally and documented the responses in writing.
Clinical data regarding tumor type, staging, dates and methods of
diagnostic procedures, and type of treatments were abstracted from
the medical records and captured in a clinical form. All the data was
then recorded in a case report form (CRF) as well as the electronic
research data capture (REDCap), following a double entry proced-
ure [18]. This study was conducted in accordance with the Good
Clinical Practice and all the previsions of the Declaration of
Helsinki.
Time intervals were defined as time from first consultation to
diagnosis and time from diagnosis to treatment. The date of first
consultation was established as the first consultation of the patient
for symptoms of breast or lung cancer, or the date of diagnostic
mammography or ultrasonography for breast cancer or chest radio-
logic study for lung cancer. The time of diagnosis was reported as
the date of a biopsy-proven pathology report. The time of treatment
initiation was the date the patient started systemic treatment with
chemotherapy for breast or lung cancer.










Sample sizes were estimated based on the assumptions about
diagnosis-to-treatment times, according to the data obtained from the
survey of local experts (real-life setting) and published studied (ideal
setting). Statistical power was set at 80% and alpha level at 0.05. For
the breast cancer population, mean time estimates (+/− standard devi-
ation) of 110 days (55) and 80 days (40) were obtained, and a sample
size of 65 patients per arm was calculated, totaling 130 individuals.
For the lung cancer population, mean time estimates (+/− standard
deviation) of 120 days (50) and 140 days (55) were obtained, result-
ing in sample size estimates equal to 99 patients per group, and 198
individuals overall.
Mean and standard deviation or median and interquartile range
(for continuous variables) as well as frequency and percentage (for
categorical variables) were used to describe the study population by
health system. Kaplan Meier curves were calculated to estimate pat-
terns in time to diagnosis and to initial treatment and groups were
compared by the log rank test. Unadjusted and Bonferroni corrected
P-values are provided for the outcomes. A Cox proportional hazard
regression model was used to explore the association between type
of health system and individual sociodemographic and clinical vari-
ables with the time from diagnosis to treatment with chemotherapy
in each cohort. Factors shown to significantly associate in the uni-
variate models were evaluated in a multivariate Cox regression
model.
For both univariate and multivariate models, we reported the
estimate hazard ratios (HR) with the 95% confidence interval (CI).
Variables associated with the time elapsed from diagnosis to treat-
ment in univariate analysis, with a P-value <0.1, were included in
multivariate analysis. Data analyses were performed using SAS soft-
ware version 9.3 (SAS Institute Inc, Cary, NC); P-values are two-
sided, with an α level of 0.05 considered statistically significant.
Ethics
The study protocol was reviewed and approved by the ethics com-
mittee of each participating institution. All patients signed an
informed consent to participate in the study, conducted in accord-
ance with the Declaration of Helsinki
Results
Between June 2016 and September 2017, 306 patients were screened
for eligibility criteria. Of these, 25 individuals did not meet the inclu-
sion criteria. Of the 281 patients who met inclusion criteria, 13
declined to participate in the study. Among 268 patients consented
and included in the study, 168 had breast cancer and 100 had lung
cancer diagnosis. The survey was conducted to all the participants.
Among the participating institutions, the provider-consultation ratio
(number of patient consultation/physician) for public hospitals was
2198, 2414 and 2365. The provider-consultation ratio for private
hospitals was 690, 1478 and 1571.
Breast cancer
A total of 168 female patients with breast cancer were included, 93
were treated in private hospitals and 75 in public hospitals. Mean
age (SD) was 50.8 (13.4) in public hospitals and 52.0 (11.0) in pri-
vate hospitals (Table 1). There was a higher proportion of foreign-
born patients consulting in the public system compared with private
hospitals (24% vs 3.3%, P < 0.0001). Regarding relationship sta-
tus, 64.5% of patients treated at private hospitals were married or
cohabiting compared to 37,3% of women in public hospitals.
Patients consulting in public hospital had lower educational level
and had lower family income compared to patients assisted at pri-
vate hospitals. Lower levels of employment were consistently
observed in patients treated at public hospitals (24% versus 69.9%,
P < 0.001). Importantly, 10.7% of patients treated in public hospi-
tals had to relocate closer to the hospital to receive care compared
to 1.1% in private hospitals. There were no significant differences
in the travel distance to public and private hospitals, when consid-
ering the patient’s location at the time of cancer diagnosis and
chemotherapy initiation. However, 69.3% of patients treated at
public hospital used public transportation compared to 29.3% of
patients in private hospitals resulting in significant longer travel
times for patients treated in public hospitals. Regarding health
insurance, 57% of patients treated in private hospitals had private
insurance and 43% had union-run health insurance. In public hos-
pitals, 46.7% of patients had union-run health insurance and
53.3% had no health insurance.
Patients treated in public hospitals had more advanced breast
cancer stage disease compared to patients treated in private facilities,
stage III in 45.3% versus 21.5% and stage IV in 13.3% versus
3.2%, respectively (P < 0.0001). Contrariwise, most patients treated
at private hospitals presented with early stage disease, stage I in
29% vs 2.7% and stage II in 45.2% vs 33.3% (P < 0.0001). There
was a significant difference in the rate of breast cancer diagnosis as
a result of screening practice, 36.6% of cases in private and 9.3% in
public hospitals. Patients treated at private hospitals had improved
performance status than their counterparts in public facilities, with
an Eastern Cooperative Oncology Group Performance Status
(ECOG PS) score of 0 in 90.3% vs 77.3% and score I in 8.6% vs
22.7% respectively. The ECOG PS is used in oncology to quantify
the functional status of patients and it ranges from 0 (fully active
without restriction) to 5 (death).
Chemotherapy modalities varied significantly between systems,
likely due to the differences in clinical stage at presentation. In pub-
lic hospitals, 46.7% of patients received neoadjuvant therapy com-
pared to 17.2% of individuals in private hospitals. Contrariwise,
adjuvant treatment was administered to 79.6% of patients in private
and 36% of patients in public hospitals. When accounting per stage,
a higher proportion of patients with stage I-II disease received
neoadjuvant treatment in public compared to private hospitals
(P < 0.0001). There were no significant differences in the treatment
modalities for patients with stage III disease (Supplementary
Table 1).
Chemotherapy drugs were provided by private insurance or
social security in 96.8% of patients in the private and 36% in public
hospitals. The public health system provided the treatment to 36%
of patients treated in the public and 1.1% in the private hospitals. In
28% of patients treated in public hospitals and 2.2% in private hos-
pitals, chemotherapy drugs were provided by the institutional phar-
macies as remaining unused drugs from other patient’s treatments.
There were no differences in the use of high cost drugs (trastuzu-
mab, pertuzumab or bevacizumab) between systems, 17.2% in pri-
vate and 18.7% in public hospitals.
Median time elapsed from diagnosis to treatment was signifi-
cantly prolonged in public compared to private hospitals, 76 days
(95% CI: 64–86) vs 60 days (95% CI: 52–65) (P = 0.0001)
(Table 2). After performing subgroup analysis, according to treat-
ment modality, the difference in time from diagnosis to treatment
was maintained in the neoadjuvant and adjuvant setting between sys-
tems (Fig. 1). In the neoadjuvant setting, median time from diagnosis
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to treatment was 57 days (95% CI: 49–75) in public and 26 days
(95% CI: 16–41) in private hospitals (P = 0.0002). Median time
from diagnosis to adjuvant treatment was 130 days (95% CI:
109–159) in public and 64 days (95% CI: 56–73) in private hospitals
(P < 0.0001). In the adjuvant setting, this difference was due to pro-
longed times from diagnosis to surgery, 50 days (95% CI: 36–67) in
public and 18 days (95% CI: 16–26) in private hospitals (P =
0.0013), as well as from surgery to chemotherapy, 83.5 (95% CI:
70–98) and 48 days (95% CI: 40–59) respectively (P < 0.0001).
Importantly, there were no significant differences between the time
elapsed from the first consultation to diagnosis between both groups,
median time for public hospitals of 43 days (95% CI: 30–57) and 35
days (95% CI: 31–41) in private hospitals (P = 0.1769).
The variables that were associated with the time from diagnosis
to chemotherapy treatment in the univariate analysis were the type
of health insurance (P = 0.001), the type of hospital (P = 0.0002),
number of inhabitants in a household (P = 0.0013), the travel dis-
tance to the hospital (P = 0.0815), age at diagnosis (P = 0.0035),
whether the patient was the main source of family income (P =
0.0056) and employment status (P = 0.0175). In multivariate ana-
lysis, treatment in a private hospital was associated with a shorter
time elapse between diagnosis and treatment (HR 2.978, P < 0.001).
Age was borderline statistically significantly associated with time to
treatment (HR 0.984, P = 0.0234).
Lung cancer
A total of 100 patients with NSCLC were included, 59 in private
and 41 in public hospitals. Mean age (SD) was 63.8 years (10.1) in
public and 64.1 years (10.0) in private hospitals (Table 3). There
was a higher proportion of men with lung cancer treated in both
systems. There were no significant differences in relationship nor
Table 1 Socio-economic, educational and clinical characteristics of patients with breast cancer treated at public and private hospitals.
(Page 8).





Age [Mean (SD] 52.0 (11.0) 50.8 (13.4) 0.5153
Nationality Argentina 90 (96.7%) 57 (76.0%) <0.0001
Other 3 (3.3%) 18 (24.0%)
Civil status Married/cohabiting 60 (64.5%) 28 (37.3%) 0.0005
Single 33 (35.5%) 47 (62.7%)
Education Incomplete primary education or inferior 2 (2.2%) 7 (9.3%) <0.0001
Complete primary / Incomplete secondary education 11 (11.8%) 29 (38.7%)
Complete secondary / incomplete tertiary education 22 (23.7%) 31 (41.3%)
Complete tertiary education 58 (62.4%) 8 (10.7%)





Employment status Employed 65 (69.9%) 18 (24.0%) <0.0001
Unemployed 10 (10.8%) 33 (44.0%)
Retired 18 (19.4%) 21 (28.0%)
Pensioner 0 (0.0%) 3 (4.0%)
Transportation to Hospital Public 25 (26.9%) 52 (69.3%) <0.0001
Private 67 (72.0%) 22 (29.3%)
Walking 1 (1.1%) 1 (1.3%)
Travel time to the hospital (min)
[Median (Q1–Q3)]
40.0 (25.0–60.0) 50.0 (30.0–90.0) 0.0028
Travel Distance (km) [Median (Q1–Q3)] 11.0 (6.0–19.0) 13.0 (5.1–30.0) 0.3418
Housing relocation for treatment 1 (1.1%) 8 (10.7%) 0.0061
Health insurance Private insurance 53 (57.0%) 0 (0.0%) <0.0001
Union-run health insurance 40 (43.0%) 35 (46.7%)
None 0 (0.0%) 40 (53.3%)
Breast Cancer stage (AJCC 7th edition) I 27 (29.0%) 2 (2.7%) <0.0001
II 42 (45.2%) 25 (33.3%)
III 20 (21.5%) 34 (45.3%)
IV 3 (3.2%) 10 (13.3%)
Relapse after definitive treatment 1 (1.1%) 4 (5.3%)
Breast cancer detection by screening 34 (36,6%) 7 (9,3%) 0.0003
Performance status (ECOG) 0 84 (90.3%) 58 (77.3%) 0.0280
1 8 (8.6%) 17 (22.7%)
2 1 (1.1%) 0 (0.0%)
Treatment modality Neoadjuvant 16 (17.2%) 35 (46.7%) <0.0001
Adjuvant 74 (79.6%) 27 (36.0%)
Palliative 3 (3.2%) 13 (17.3%)
High cost drugs 16 (17.2%) 14 (18.7%) 0.8414
Chemotherapy drug provider Health insurance 90 (96.8%) 27 (36.0%) <0.0001
Provided by the State 1 (1.1%) 27 (36.0%)
Hospital Pharmacy (unused medication) 2 (2.2%) 21 (28.0%)
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smoking status between patients treated at public and private hospi-
tals. Patients treated in public hospitals had significantly lower levels
of education (P < 0.0001), rates of employment (P = 0.0074) and
family income (P < 0.0001) compared to patients treated in private
hospitals. Patients treated in public hospitals had to travel signifi-
cantly longer distances to reach the hospital (P = 0.0255) which
resulted in prolonged travel times compared to patients treated in
private hospitals (p = 0.0007). With respect to health insurance,
41.5% of patients treated in public hospitals had no health insur-
ance and 56.1% had union-run insurance. In private hospitals,
62.7% of patients had private insurance and 37.3% had union-run
health insurance.
Most patients in both groups presented with advance disease at
diagnosis: metastatic disease (stage IV) in 73.2% in the public and
59.3% in the private hospitals and locally advanced disease (stage
III) in 17.1% and 30.5% of patients, respectively. Only 9.8% of
patients in the public and 10.2% in private hospitals presented with
stage I or II disease. Lung adenocarcinoma was the predominant
histological subtype of NSCLC in both groups, 83.1% in private
and 61% in public hospitals. There was a higher proportion of
squamous cell carcinoma histology in public hospitals, 31.7% vs
13.6% (p = 0.03).
Chemotherapy was mostly administered in the context of meta-
static (stage IV) disease in both groups. There was a higher propor-
tion of chemoradiation therapy in private hospitals, 32.2% vs
12.2% (P = 0.03). Adjuvant treatment was administered to 11.9%
of patients in private and 9.8% in public hospitals. There were no
significant differences in performance status between the groups,
with 88.1% in the private and 85.3% in the public group having
ECOG scores 1–2. Chemotherapy drugs were provided by private
insurance or social security in 96.6% of patients treated at private
hospitals. In patients treated in public hospitals, treatment drugs
were provided by union-run health insurance in 42.5% of the cases
and the public health system in 35%. A total of 22.5% of patients
received chemotherapy drugs provided by the hospital pharmacies
as remaining unused drugs in public hospitals compared to 3.4% in
private institutions.
Time elapsed from diagnosis to chemotherapy treatment was sig-
nificantly higher in public hospitals, median time of 71 days (95%
CI: 60–83) in public compared to 31 days (95% CI: 24–39) in pri-
vate hospitals (P = 0.0002) (Table 2). In a subgroup analysis by
treatment modality this difference was maintained for patients trea-
ted in the metastatic setting, with a median time of 63 days (95%
CI: 45–83) and 33 days (95% CI: 26–44) respectively (P = 0.005)
(Fig. 2). For patients treated with neoadjuvant, adjuvant or chemor-
adiation therapy, median time from diagnosis to treatment was 83
days (95% CI: 64–99) in the public hospitals and 22 days (95% CI:
14–37) in private hospitals (P = 0.0091). Median time from first
consultation to diagnosis was 86 days (95% CI: 69–116) in public
and 48 days (95% CI: 33–61) in private hospitals (P = 0.0014).
We performed multivariate analysis to study the association of
variables inherent to the health system and to patients with lung
cancer, with the time elapsed from diagnosis to chemotherapy treat-
ment. Significant variables in univariate analysis were: type of hos-
pital (P = 0.0003), type of transportation (P = 0.0005), type of
health insurance (P = 0.022), employment (P = 0.0284), education
level (P = 0.0732) and histological type (P = 0.087). In multivariate
analysis, attention in a private hospital [HR 1.99 (95% CI:
1.27–3.11)] and private transportation [HR 2.12 (95% CI:
1.35–3.32)] were significantly associated with shorter times from
diagnosis to chemotherapy treatment. As the point of analysis is the
time, a positive hazard ratio reflects that it is more likely to have
shorter treatment delays in a private hospital with respect to public
hospitals.
Discussion
Timely access to cancer diagnosis and treatment is a key factor to
guarantee high quality medical care for patients. Health coverage is
a fundamental determinant of access to medical attention, but these
two concepts differ substantially. The Argentinean National Cancer
Institute (INC) reported from a nationwide registry, with data
mainly aggregated from public hospitals, the time elapsed from first
consultation to diagnosis and from diagnosis to treatment for mul-
tiple cancer types [19]. The current study provides further informa-
tion regarding the access to cancer diagnosis and treatment between
the private and public health system in our country.
In this study, we described inequities in timely access to treat-
ments with chemotherapy for patients with breast and lung cancer
between the public and private health systems in the city of Buenos
Aires, Argentina. We observed a two-fold time difference in the initi-
ation of adjuvant and neoadjuvant treatments in public compared to
Table 2 Primary Outcome: times from diagnosis to treatment with chemotherapy for patients with breast cancer and lung cancer
diagnosis in private and public hospitals. Secondary outcome: time from first consultation to cancer diagnosis. (Pages 10 and 12).







Diagnosis to chemotherapy (global) 93 60 (52–65) 75 76 (64–86) 0.0001 0.0006
Diagnosis to neoadjuvant treatment 16 26 (16–41) 35 57 (49–75) 0.0002 0.0012
Diagnosis to adjuvant treatment 74 64 (56–73) 27 130 (109–159) <0.0001 0.0006
Diagnosis to surgery 74 18 (16–26) 27 50 (36–67) 0.0013 0.0076
Surgery to chemotherapy 74 48 (40–59) 27 83.5 (70–98) <0.0001 0.0006
First consultation to diagnosis 93 35 (31–41) 75 43 (30–57) 0.1769 1.0000
Lung cancer cohort
Diagnosis to chemotherapy (global) 59 31 (24–39) 41 71 (60–83) 0.0002 0.0008
Diagnosis to chemotherapy treatment in metastatic disease 33 33 (26–44) 30 63 (45–83) 0.005 0.0200
Diagnosis to neoadjuvant, adjuvant or chemoradiation therapy 26 22 (14–37) 11 83 (64–99) 0.0091 0.0364
First consultation to diagnosis 59 48 (33–61) 41 86 (69–116) 0.0014 0.0056






/intqhc/article/31/9/682/5498287 by guest on 02 D
ecem
ber 2021
private hospitals in patients with breast cancer. In the adjuvant
setting, this difference was comprised of prolonged delays in time
from diagnosis to surgery and from surgery to chemotherapy.
Importantly, the time from first consultation to diagnosis was simi-
lar between public and private hospitals, highlighting that timely
breast cancer diagnosis by core biopsy is achieved in both systems.
Mosunjac et al., report similar findings in Atlanta, USA. In their
study, the time elapsed from diagnosis to surgery (47 versus 33
days) and adjuvant chemotherapy (25 versus 18 days) were longer
in public compared to private hospitals, without differences in time
from first consultation to diagnosis [20]. In the study reported here,
patients consulting in public hospitals presented with more
advanced disease stage and lower rates of diagnosis by breast cancer
screening. Similar results were reported in Brazil, where patients
treated in public hospitals had significantly higher clinical stage at
diagnosis, lower rates of chemotherapy use and longer delays to
treatment compared to patients in private hospitals [21]. Women
with lower income and educational levels achieve lower rates of
breast cancer screening, which has been associated with disease pres-
entation in more advanced stages [22].
In the lung cancer cohort, we observed a two-fold difference in
time to chemotherapy for patients with metastatic disease and a
nearly four-fold difference in the median time to treatment for
patients receiving neoadjuvant, adjuvant or chemoradiation therapy.
Similarly, disparities in the time to lung cancer treatment have been
reported in high-income countries, associated with the type of health
insurance and healthcare facility [23]. The time elapsed from first
consultation to lung cancer diagnosis was also significantly pro-
longed in patients treated at public hospitals compared to private
institutions.
Compared to patients with breast cancer, where diagnosis by
ultrasound guided biopsies of the breast is less complex and more
widely available, patients with lung cancer most often present with a
variety of symptoms, frequently requiring hospitalization. Lung can-
cer diagnosis requires invasive procedures like endoscopy, surgical
or CT-guided biopsies and multiple staging studies [24, 25]. This
could account for the differences observed in the time intervals from
first consultation to diagnosis between private and public hospitals
in our study, where the access to imaging studies and invasive diag-
nostic procedures vary significantly. The symptomatic onset and
complexity in diagnosing lung cancer, often requiring the input of
highly specialized medical professionals, could also explain why
patients are required to travel longer distances to consult in specia-
lized academic public hospitals, while those diagnosed with breast
cancer may receive adequate care closer to their home.
The retrospective cohort design of the study allowed for an
accurate assessment of multiple social, demographic, educational
and economic factors related to the individuals and their families.
These factors differed significantly between patients treated in pri-
vate and public hospitals in Buenos Aires. Socioeconomic factors
like education, income and employment are known to influence the
access to breast and lung cancer diagnosis and treatment [26–28].
Patients seeking treatment in public hospitals had lower educational
level, lower employment rates and family income compared to
patients in the private system. These factors are likely contributing
to the delays in cancer treatment for patients attending public hospi-
tals, but in the present study, the analysis of socioeconomic factors
on the time to treatment was limited by the sample size. Population
based studies from broader registries could potentially identify
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Further research is also needed to identify barriers leading to
health system delays. In this study, the type of hospital (public/pri-
vate) was independently associated with delays to chemotherapy
treatment initiation in a multivariate analysis. We hypothesize that
multiple factors can contribute to the delays in cancer diagnosis and
treatment observed in public hospitals. There is a higher physician-
consultation ratio in public hospitals that can translate into pro-
longed waiting times for outpatient consultations. In addition, there
are important differences in the management, infrastructure and
technological resources between public and private hospitals that
likely contribute to the observed disparities [29]. The private health
system counts with higher number of diagnostic imaging apparel,
rapid access to diagnostic testing and surgical therapeutic interven-
tions. Time to drug approvals and dispensing is usually more eficient
in the private health system compared to state oncology drug banks,
influencing timely access to treatments.
This is the first study, to our knowledge, to describe disparities
in cancer care access between public and private health systems in
Argentina. Disparities in cancer access can vary significantly by geo-
graphical localization. The present study included only patients trea-
ted at academic hospitals from the city of Buenos Aires and therefor,
cannot be generalized to other regions of the country.
Identifying disparities in the access of patients to cancer diagno-
sis and treatment can guide future interventions to design health
Table 3 Socio-economic, educational and clinical characteristics of patients with lung cancer treated at public and private hospitals. (Page 11).





Age [Mean (SD)] 64.1 (10.0) 63.8 (10.1) 0.8793
Sex Male 35 (59.3%) 26 (63.4%) 0.6798
Female 24 (40.7%) 15 (36.6%)
Nationality Argentina 59 (100%) 34 (82.9%) 0.0014
Other 0 (0.0%) 7 (17.1%)
Civil status Married/cohabiting 17 (28.8%) 21 (51.2%) 0.0232
Single 42 (71.2%) 20 (48.8%)
Smoking status Current 7 (11.9%) 5 (12.2%) 0.6974
Former 46 (78.0%) 34 (82.9%)
Non-smoker 6 (10.2%) 2 (4.9%)
Education Incomplete Primary education or inferior 0 (0.0%) 3 (7.3%) <0.0001
Complete primary / Incomplete secondary education 4 (6.8%) 23 (56.1%)
Complete secondary / incomplete tertiary education 17 (28.8%) 9 (22.0%)








Employment status Employed 32 (54.2%) 11 (26.8%) 0.0074
Unemployed 5 (8.5%) 11 (26.8%)
Retired 22 (37.3%) 19 (46.4%)
Distance (km)
[Median (Q1–Q3)]
10 (6–14.8) 20 (5.8–35) 0.0255
Housing relocation for treatment Yes 2 (3.4%) 4 (9.8%) 0.224
Transportation to Hospital Public 8 (13.6%) 24 (58.5%) <0.0001
Private 50 (84.7%) 15 (36.6%)
Walking 1 (1.7%) 2 (4.9%)
Travel time to the hospital (min)
[Median (Q1–Q3)]
30 (20–40) 60 (30–90) 0.0007
Health insurance Private Insurance 37 (62.7%) 1 (2.4%) <0.0001
Union-run health insurance 22 (37.3%) 23 (56.1%)
None 0 (0.0%) 17 (41.5%)
Lung Cancer stage (AJCC 7th edition) I/II 6 (10.2%) 4 (9.8%) 0.2916
III 18 (30.5%) 7 (17.1%)
IV or relapsed 35 (59.3%) 30 (73.2%)
Histology Adenocarcinoma 49/ 59 (83.1%) 25/ 41 (61.0%) 0.0369
Squamous Cell Carcinoma 8/ 59 (13.6%) 13/ 41 (31.7%)
Other 2/ 59 (3.4%) 3/ 41 (7.3%)
Treatment modality Neoadjuvant 0 (0.0%) 2 (4.9%) 0.0329
Adjuvant 7 (11.9%) 4 (9.8%)
Chemoradiotherapy 19 (32.2%) 5 (12.2%)
Palliative 33 (55.9%) 30 (73.2%)
Performance Status (ECOG) 1 31 (52.5%) 12 (29.3%) 0.6854
2 21 (35.6%) 23 (56%)
3 7 (11.9%) 6 (14.6%)
Chemotherapy drug provider Health insurance 57 (96.6%) 17/ 40 (42.5%) <0.0001
Provided by the State 0 (0.0%) 14/ 40 (35.0%)
Hospital Pharmacy (unused medication) 2 (3.4%) 9/ 40 (22.5%)
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policies aiming to improve the quality of health systems and assist
populations at risk of delayed cancer care.
Supplementary material
Supplementary material is available at International Journal for Quality in
Health Care online.
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